Breaking barriers in guideline-based RAASi therapy: Solving issues with hyperkalemia

3 episodes
1.00 program credits
Overview image
  • Overview

    Despite the proven benefits of RAASi-based therapy, RAASi therapy is often underused in clinical practice. In this series, three experts discuss the reasons and clinical consequences of suboptimal RAASi therapy in patients with HF, and focus on how to solve issues with hyperkalemia. 

    This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.

  • Program Highlights

    This educational program consists of three presentations on HF and hyperkalemia.

    Continuing foundational therapy in symptomatic HF: the key role of RAASi-based therapy  - Shelley Zieroth, MD - Winnipeg, MB, Canada

    • Clinicians prescribing RAASi therapy for HF may face challenges in the management of patients, such as the occurence of hyperkalemia. Shelley Zieroth discusses the importance of achieving and maintaining optimal RAASi therapy in patients with HF.

    But what to do if potassium level goes up? - Mikhail Kosiborod, MD - Kansas City, MO, USA

    • What are the management options for patients with HF and hyperkalemia? Mikhail Kosiborod presents a patient case and gives an answer to this question.

    Practical experience and model for optimizing RAASi-based therapy in HF - Aaron Wong, MD - Bridgend, Wales, UK

    • Aaron Wong presents real-world data that show that a novel potassium binder can be used to optimize RAASi therapy in patients with HF.
  • Instructions

    • Watch the three lectures and answer the pre- and post-test questions
    • Fill in the evaluation questions
    • Download CME Certificate

    For questions regarding this activity, please contact us at

  • Learning Objectives

    • Describe the causes, incidence and clinical consequences of suboptimal RAASi-based therapy in patients with HF
    • Recall the current management options for patients with HF and hyperkalemia
    • Recall recent trial data of novel selective potassium binders
    • Describe how management of hyperkalemia can enable optimization of RAASi-based therapy in patients with HF
  • Target Audience

    This educational activity is designed for all healthcare professionals with an interest in management of patients with HF and hyperkalemia.

  • Accreditation and Credit Designation Statements

    This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

    Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

  • Commercial Support

    Funding for this educational program was provided by unrestricted educational grants from AstraZeneca.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free